

Physician - Pediatric Cardiac and Vascular Surgery/Adult Congenital Heart Diseases

[MÖB-06]

Clinical Outcomes of Injectable Biopulmonic Valve Replacement vs. Conventional Pulmonary Valve Replacement in Tetralogy of Fallot Patients with Severe Pulmonary Regurgitation: A Comparative Study

Sercan Tak¹, Murat Koç², Ali Kutsal³, Vehbi Doğan⁴

¹Department of Cardiovascular Surgery, Gazi University Faculty of Medicine, Ankara, Türkiye

²Department of Cardiovascular Surgery, Etlik City Hospital, Ankara, Türkiye

³Department of Cardiovascular Surgery, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Türkiye

⁴Department of Pediatric Cardiology, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Türkiye

Cardiovascular Surgery and Interventions 2024;11(Suppl 1):MÖB-06

Doi: 10.5606/e-cvsi.2024.mob-06

E-mail: sercantak@gmail.com

Received: September 13, 2024 - Accepted: September 29, 2024

Objective: This study aimed to compare early- to mid-term outcomes of injectable biopulmonic valve replacement without cardiopulmonary bypass and conventional pulmonary valve replacement in patients with severe pulmonary regurgitation following tetralogy of Fallot (TOF) corrective surgery.

Methods: The study was conducted with 22 patients between ?? 2011 and ?? 2020. Injectable pulmonary valve replacement was performed in nine patients, while 13 patients underwent bioprosthetic aortic valve replacement using a conventional surgical approach. An injectable valve was chosen for patients with a pulmonary annulus diameter ≤ 30 mm and ≥ 15 mm when there was no need for additional procedures.

Results: Comparing postoperative outcomes between the injectable valve group and the conventional surgery group, the mean duration of intensive care unit stay was 16.78 ± 6.22 vs. 37.00 ± 23.43 h ($p=0.003$); the mean postoperative mechanical ventilation time was 5.22 ± 3.93 vs. 15.38 ± 23.43 h ($p=0.001$); the mean volume of chest tube drainage was 206.67 ± 108.16 mL vs. 513.08 ± 274.11 mL ($p=0.003$); the mean inotropic score was 5.00 ± 5.59 vs. 10.96 ± 8.98 ($p=0.05$); the mean vasoactive score was 6.11 ± 8.20 vs. 12.11 ± 10.40 ($p=0.04$); and the mean length of hospital stay was 5.44 ± 2.35 vs. 8.38 ± 3.09 days ($p=0.04$).

Conclusion: Injectable pulmonary valve replacement, which can be applied without cardiopulmonary bypass, has advantages such as being less invasive and having better postoperative results compared to the conventional procedure. However, more comprehensive studies with long-term results are needed.

Keywords: Tetralogy of Fallot, pulmonary valve replacement, injectable valve.

REFERENCES

- van der Ven JPG, van den Bosch E, Bogers AJCC, Helbing WA. Current outcomes and treatment of tetralogy of Fallot. *F1000Res* 2019;8:F1000 Faculty Rev-1530. doi: 10.12688/f1000research.17174.1.
- Marelli AJ, Mackie AS, Ionescu-Iltu R, Rahme E, Pilote L. Congenital heart disease in the general population: Changing prevalence and age distribution. *Circulation* 2007;115:163-72. doi: 10.1161/CIRCULATIONAHA.106.627224.
- Borowski A, Ghodsizad A, Litmathe J, Lawrenz W, Schmidt KG, Gams E. Severe pulmonary regurgitation late after total repair of tetralogy of Fallot: Surgical considerations. *Pediatr Cardiol* 2004;25:466-71. doi: 10.1007/s00246-003-0579-z.
- Kirklin JK, Kirklin JW, Blackstone EH, Milano A, Pacifico AD. Effect of transannular patching on outcome after repair of tetralogy of Fallot. *Ann Thorac Surg* 1989;48:783-91. doi: 10.1016/0003-4975(89)90671-1.
- Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: A multicentre study. *Lancet* 2000;356:975-81. doi: 10.1016/S0140-6736(00)02714-8.
- Ho KW, Tan RS, Wong KY, Tan TH, Shankar S, Tan JL. Late complications following tetralogy of Fallot repair: The need for long-term follow-up. *Ann Acad Med Singap* 2007;36:947-53.
- Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e637-97. doi: 10.1161/CIR.0000000000000602.